668 related articles for article (PubMed ID: 32198123)
1. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S
Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
3. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
4. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
Diallo A; Carlos-Bolumbu M; Galtier F
Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
Scheen AJ
Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
[TBL] [Abstract][Full Text] [Related]
8. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
[TBL] [Abstract][Full Text] [Related]
9. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes.
Cattadori G; Pantanetti P; Ambrosio G
Diabetes Res Clin Pract; 2019 Nov; 157():107835. PubMed ID: 31479706
[TBL] [Abstract][Full Text] [Related]
10. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
[TBL] [Abstract][Full Text] [Related]
11. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
13. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
North EJ; Newman JD
Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
[TBL] [Abstract][Full Text] [Related]
14. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
Ludwig L; Darmon P; Guerci B
Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
[TBL] [Abstract][Full Text] [Related]
15. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.
Giugliano D; Scappaticcio L; Longo M; Bellastella G; Esposito K
Cardiovasc Diabetol; 2021 Oct; 20(1):205. PubMed ID: 34641876
[TBL] [Abstract][Full Text] [Related]
17. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
[TBL] [Abstract][Full Text] [Related]
18. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
Sinha B; Ghosal S
Diabetes Res Clin Pract; 2019 Apr; 150():8-16. PubMed ID: 30794833
[TBL] [Abstract][Full Text] [Related]
19. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
Packer M
Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
[No Abstract] [Full Text] [Related]
20. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2020; 14(3):181-187. PubMed ID: 32142999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]